对多发性硬化症患者的疾病修饰药物停药的回顾性分析 (S31.010)
Gnaneswari Karayi1, Natalia Quinones-Herrero2, Janice Martin3
1Brown University.
Neurology
|February 20, 2025
概括
停止服用多发性硬化症 (MS) 修饰疾病药物 (DMDs) 的患者面临疾病活性风险,特别是年轻人以及服用fingolimod或natalizumab的人. 老年患者或残疾分数较高的患者在停止治疗后风险较低.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 多发性硬化症 (MS) 疾病修饰药物 (DMDs) 对于管理这种疾病至关重要.
- 切断DMD是常见的,但疾病活动 (DA) 的结果和风险仍然不完全理解.
- 现有关于DMD停药的研究提供了关于后续MS活动风险的不确证据.
研究的目的:
- 在停止服用疾病修饰药物 (DMDs) 后,分析多发性硬化症 (MS) 患者的疾病活动 (DA) 风险.
- 为了确定患者的特征和特定的DMD与更高的风险相关的DA停药后.
主要方法:
- 对被诊断患有多发性硬化症的患者进行了回顾性分析,这些患者停止了DMDs.
- 从2020年至2023年期间从单个学术中心收集的数据.
- 在DMD停止后评估疾病活动,包括MRI发现和复发.
主要成果:
- 在停止使用DMD的170名患者中,15.8% (27名患者) 患有疾病活性 (DA).
- 在停止服用fingolimod (58%) 和natalizumab (30%) 的患者中观察到较高的DA率.
- 年轻的患者 (平均年龄为48) 和EDSS得分较低的患者 (2.8) 更有可能发展DA.
结论:
- 年轻的多发性硬化患者的残疾分数较低,在停止DMD治疗后疾病活动的风险增加.
- 停止使用芬戈利莫德和纳塔利祖马布与随后疾病活动的风险显著增加有关.
- 60岁以上的患者和EDSS得分大于6的患者似乎在停药后患有DA的风险最低.
相关概念视频
Pharmacovigilance
764
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
764
Assumptions of Survival Analysis
84
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
84
Desensitization and Tachyphylaxis
1.5K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.5K
Analysis of Population Pharmacokinetic Data
216
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
216
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
131
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
131
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
70
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
70


